Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong
treatment is required and there is no cure. HIV can integrate in the host genome and persist …

HIV-1-infected cells that persist despite antiretroviral therapy (ART) are frequently
considered" transcriptionally silent," but active viral gene expression may occur in some …

Medical case reports suggest that cannabinoids extracted from Cannabis sativa have
therapeutic effects; however, the therapeutic employment is limited due to the psychotropic …

HIV-1 persists in a latent reservoir in resting CD4+ T cells despite antiretroviral therapy
(ART). The reservoir decays slowly over the first 7 years of ART (t 1/2= 44 months). However …

Sustained, drug-free control of HIV-1 replication is naturally achieved in less than 0.5% of
infected individuals (here termed 'elite controllers'), despite the presence of a replication …

Attempts to reduce the human immunodeficiency virus type 1 (HIV-1) reservoir and induce
antiretroviral therapy (ART)-free virologic control have largely been unsuccessful. In this …

A stable latent reservoir for HIV-1 in resting CD4+ T cells is the principal barrier to a cure,–.
Curative strategies that target the reservoir are being tested, and require accurate, scalable …

The T‐cell response is central in the adaptive immune‐mediated elimination of pathogen‐
infected and/or cancer cells. This activated T‐cell response can inflict an overwhelming …

Background Antiretroviral therapy (ART) halts HIV-1 replication, decreasing viremia to below
the detection limit of clinical assays. However, some individuals experience persistent …